CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

15 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15

08 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award

02 Mar 2023 08:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan

16 Feb 2023 08:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

25 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program

19 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform

12 Jan 2023 08:26:27 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

10 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10

03 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022

06 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Investor Conferences

07 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

10 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

19 Jul 2022 08:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study

27 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference

17 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

25 May 2022 08:00:02 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference

18 May 2022 08:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

10 May 2022 15:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10

03 May 2022 07:30:00 By Nasdaq GlobeNewswire